Michael David Morgan

Michael David Morgan

Auto-generated profile, based on publicly available information

Michael David Morgan

Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2018 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LHLaleh Haghverdi
Laleh Haghverdi
ALAaron T L Lun
Aaron T L Lun
MMMichael D Morgan
Michael D Morgan
JMJohn C Marioni
John C Marioni

30 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EDEmma Dann
Emma Dann
NHNeil C. Henderson
Neil C. Henderson
STSarah A. Teichmann
Sarah A. Teichmann
MMMichael D. Morgan
Michael D. Morgan
JMJohn C. Marioni
John C. Marioni

20 April 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ESEmily Stephenson
Emily Stephenson
GRGary Reynolds
Gary Reynolds
RBRachel A. Botting
Rachel A. Botting
FCFernando J. Calero-Nieto
Fernando J. Calero-Nieto
MMMichael D. Morgan
Michael D. Morgan
MHMuzlifah Haniffa
Muzlifah Haniffa
Analysis of human blood immune cells provides insights into the coordinated response to viral infections such as severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19). We performed single-cell transcriptome, surface proteome and T and B lymphocyte antigen receptor analyses of over 780,000 peripheral blood mononuclear cells from a cross-sectional cohort of 130 patients with varying severities of COVID-19. We identified expansion of nonclassical monocytes expressing complement transcripts (CD16+C1QA/B/C+) that sequester platelets and were predicted to replenish the alveolar macrophage pool in COVID-19. Early, uncommitted CD34+hematopoietic stem/progenitor cells were primed toward megakaryopoiesis, accompanied by expanded megakaryocyte-committed progenitors and increased platelet activation. Clonally expanded CD8+T cells and an increased ratio of CD8+effector T cells to effector memory T cells characterized severe disease, while circulating follicular helper T cells accompanied mild disease. We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion of plasmablasts and plasma cells. Our study highlights the coordinated immune response that contributes to COVID-19 pathogenesis and reveals discrete cellular components that can be targeted for therapy.

8 September 2021 in Nature
Verified
Journal Article
Open access
PDF file
RERasa Elmentaite
Rasa Elmentaite
NKNatsuhiko Kumasaka
Natsuhiko Kumasaka
KRKenny Roberts
Kenny Roberts
AFAaron Fleming
Aaron Fleming
EDEmma Dann
Emma Dann
STSarah A. Teichmann
Sarah A. Teichmann
The cellular landscape of the human intestinal tract is dynamic throughout life, developing in utero and changing in response to functional requirements and environmental exposures. Here, to comprehensively map cell lineages, we use single-cell RNA sequencing and antigen receptor analysis of almost half a million cells from up to 5 anatomical regions in the developing and up to 11 distinct anatomical regions in the healthy paediatric and adult human gut. This reveals the existence of transcriptionally distinct BEST4 epithelial cells throughout the human intestinal tract. Furthermore, we implicate IgG sensing as a function of intestinal tuft cells. We describe neural cell populations in the developing enteric nervous system, and predict cell-type-specific expression of genes associated with Hirschsprung’s disease. Finally, using a systems approach, we identify key cell players that drive the formation of secondary lymphoid tissue in early human development. We show that these programs are adopted in inflammatory bowel disease to recruit and retain immune cells at the site of inflammation. This catalogue of intestinal cells will provide new insights into cellular programs in development, homeostasis and disease.

1 June 2021 in Immunity
Verified
Journal Article
Open access
LBLaura Bergamaschi
Laura Bergamaschi
FMFederica Mescia
Federica Mescia
LTLorinda Turner
Lorinda Turner
AHAimee L. Hanson
Aimee L. Hanson
PKPrasanti Kotagiri
Prasanti Kotagiri
KSKenneth G.C. Smith
Kenneth G.C. Smith
The kinetics of the immune changes in COVID-19 across severity groups have not been rigorously assessed. Using immunophenotyping, RNA sequencing and serum cytokine analysis, we analyzed serial samples from 207 SARS-CoV2-infected individuals with a range of disease severities over 12 weeks from symptom onset. An early robust bystander CD8+ T cell immune response, without systemic inflammation, characterized asymptomatic or mild disease. Hospitalized individuals had delayed bystander responses and systemic inflammation that was already evident near symptom onset, indicating that immunopathology may be inevitable in some individuals. Viral load did not correlate with this early pathological response, but did correlate with subsequent disease severity. Immune recovery is complex, with profound persistent cellular abnormalities in severe disease correlating with altered inflammatory responses, with signatures associated with increased oxidative phosphorylation replacing those driven by cytokines tumor necrosis factor (TNF) and interleukin (IL)-6. These late immunometabolic and immune defects may have clinical implications.

21 May 2019 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
NENils Eling
Nils Eling
MMMichael D. Morgan
Michael D. Morgan
JMJohn C. Marioni
John C. Marioni